Kelun-Biotech（6990.HK）is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC or novel XDC projects in clinical or preclinical research stage.
Company Details
- Employees
- 3
- Address
- 四川, Cn
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://en.kelun-biotech.com/
- HQ
- 四川
Kelun-Biotech Questions
Kelun-Biotech's website is https://en.kelun-biotech.com/
Kelun-Biotech's LinkedIn profile is https://cn.linkedin.com/company/kelun-biotech
Kelun-Biotech has
3 employees.
View email and phone details for 3
employees at Kelun-Biotech.
Kelun-Biotech's industry is
Biotechnology Research
Kelun-Biotech's top competitors are
Splicebio,
Elkedonia,
Citius Pharmaceuticals, Inc.,
Sichuan Kelun Pharmaceutical Co., Ltd.,
Merus N.v.,
Antares Therapeutics,
Qurebio,
Allay Therapeutics,
Duoning,
Mosanna Therapeutics.
Kelun-Biotech's categories are Biotechnology Research
